NEW YORK, Oct. 17, 2023 (GLOBE NEWSWIRE) — Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies.
Moore Kuehn is investigating whether the Boards of the below companies 1) acted to maximize shareholder value, 2) failed to disclose material information, and 3) conducted a fair process:
- SP Plus Corporation (NASDAQ: SP)
SP Plus Corporation has agreed to merge with Metropolis Technologies. Under the proposed transaction SP Plus shareholders will receive $54.00 in cash per share.
- Orchard Therapeutics plc (NASDAQ: ORTX)
Orchard Therapeutics has agreed to merge with Kyowa Kirin Co. Under the proposed transaction Orchard Therapeutics shareholders will receive $16.00 in cash and a contingent value right (“CVR”) of up to $1.00 per American Depositary Share.
- Mirati Therapeutics, Inc. (NASDAQ: MRTX)
Mirati Therapeutics has agreed to merge with Bristol Myers Squibb. Under the proposed transaction, Mirati Therapeutics shareholders will receive $58.00 in cash and a CVR of up to $12.00 per share.
- Startek, Inc. (NYSE: SRT)
Startek has agreed to merge with funds managed by Capital Square Partners. Under the proposed transaction, Startek shareholders will receive $4.30 in cash per share.
Moore Kuehn encourages shareholders who would like to discuss their rights to contact Justin Kuehn, Esq. by email at jkuehn@moorekuehn.com. The consultation and case are free with no obligation to you. Moore Kuehn pays all case costs and does not charge its investor clients. Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
Moore Kuehn is a 5-star Google client-rated New York City law firm with attorneys representing investors and consumers in litigation involving securities laws, fraud, breaches of fiduciary duties, and other claims. For additional information about Moore Kuehn, please visit http://www.moorekuehn.com/practice/new-york-securities-litigation/.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contacts:
Moore Kuehn, PLLC
Justin Kuehn, Esq.
30 Wall Street, 8th Floor
New York, New York 10005
jkuehn@moorekuehn.com
(212) 709-8245
- Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve APDS diagnosis - June 24, 2025
- Hapbee Technologies Inc. Closes 2024 with Record Q4 Device Sales, Global Distribution Partnerships and Strategic Board Appointments - June 24, 2025
- WatchGuard Launches Total MDR to Deliver Full-Stack AI-Driven Security to MSPs Within One Platform - June 24, 2025
